Derik De Bruin
Stock Analyst at B of A Securities
(3.73)
# 763
Out of 5,116 analysts
222
Total ratings
67.79%
Success rate
16.64%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Buy | $43 → $60 | $48.12 | +24.69% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $138.32 | +19.29% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,417.16 | -1.92% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $231.47 | -4.96% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $37.76 | -28.50% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $96.78 | +13.66% | 3 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $16.72 | -22.25% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $45.48 | +16.53% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $384.83 | -2.55% | 14 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $6.54 | +68.20% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $101.54 | -35.99% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $12.30 | +30.08% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $579.12 | +13.97% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $226.02 | +3.97% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $203.16 | +3.37% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $276.66 | +28.32% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $20.95 | +24.11% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $254.46 | +6.50% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $175.92 | +3.46% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $17.72 | +18.51% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $18.38 | +74.10% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $135.32 | -26.10% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $74.50 | +15.44% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.13 | +315.34% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.84 | +253.26% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $183.73 | +41.51% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $8.91 | +1,246.80% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $125.49 | -4.37% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.78 | +405.62% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $688.18 | -65.85% | 3 | Nov 2, 2018 |
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $48.12
Upside: +24.69%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $138.32
Upside: +19.29%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,417.16
Upside: -1.92%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $231.47
Upside: -4.96%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $37.76
Upside: -28.50%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $96.78
Upside: +13.66%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $16.72
Upside: -22.25%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $45.48
Upside: +16.53%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $384.83
Upside: -2.55%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $6.54
Upside: +68.20%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $101.54
Upside: -35.99%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $12.30
Upside: +30.08%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $579.12
Upside: +13.97%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $226.02
Upside: +3.97%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $203.16
Upside: +3.37%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $276.66
Upside: +28.32%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $20.95
Upside: +24.11%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $254.46
Upside: +6.50%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $175.92
Upside: +3.46%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $17.72
Upside: +18.51%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $18.38
Upside: +74.10%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $135.32
Upside: -26.10%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $74.50
Upside: +15.44%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.13
Upside: +315.34%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.84
Upside: +253.26%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $183.73
Upside: +41.51%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $8.91
Upside: +1,246.80%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $125.49
Upside: -4.37%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.78
Upside: +405.62%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $688.18
Upside: -65.85%